Study guide
1.2 Registration, Fees and Candidate Decisions
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
1.2 Registration, Fees and Candidate Decisions
Key Takeaways Explain This Topic AI
CCRA early-bird totals are $435 for members and $485 for nonmembers.
CCRA regular totals are $460 for members and $600 for nonmembers.
The June 2026 handbook distinguishes eligible retest examination fees from a new full application.
Last updated: October 2026
Registration, Fees and Candidate Decisions
- Registration category ACRP member total Nonmember total
- Early bird $435 $485
- Regular $460 $600
These totals include application and examination fees. The June 2026 handbook separates early-bird member fees into $135 application plus $300 exam; regular member fees are $135 plus $325. Nonmember early-bird fees are $135 plus $350, and regular fees are $200 plus $400. There is no additional universal $50 late-registration surcharge in this schedule.
Spring testing runs February 15–May 15 and fall testing July 15–October 15. The current page lists spring early-bird registration October 20–December 31 and regular registration January 1–April 30; fall early-bird registration May 20–July 15 and regular registration July 16–September 30. These are programme windows, not a guarantee of an available PSI appointment. Schedule after receiving eligibility confirmation.
The June 2026 handbook permits retesting 60 days after the original appointment or in the next available testing window, subject to eligibility and scheduling. An eligible immediate retest requires the examination fee rather than the initial full application total: member $300–$325 or nonmember $350–$400 under that fee table.
After two unsuccessful attempts, or expiry of the one-year application eligibility, a new application and current fees are required. Consult ACRP if window and waiting-period wording leaves your particular appointment uncertain.
Credential maintenance is biennial. Use ACRP's current maintenance handbook for its continuing education, professional activity and fee rules; passing once does not create lifetime certification. ACRP does not publish a universal raw passing percentage or a first-attempt pass rate in the current sources checked here. Budget study time from your own ECO diagnostic results rather than an unsupported pass-rate prediction.
Critical Candidate Misconceptions & Testing Traps
To pass the CCRA examination on the first attempt, candidates must anticipate common psychometric traps and discard flawed assumptions:
Trap 1: The "Raw Percentage" Calculation
Many candidates believe they need a 70% or 75% raw score to pass. When encountering several difficult questions early in the exam, anxiety spikes, leading to rushed decisions. In reality, the scaled 600 cut score accounts for form difficulty. If a test form contains unusually complex scenario items, the psychometric scaling adjusts accordingly. Remain calm and focus on each question individually.
Trap 2: The "Pretest Detection" Game
Candidates sometimes try to outsmart the exam by identifying and guessing on questions they assume are unscored pretest items. Pretest items are selected from the same item-writing workshops as active items and cover the identical six domains. Devoting time to guessing which items are experimental wastes critical cognitive energy and frequently leads candidates to blow past scored questions.
Trap 3: The "Local Regulation" Reflex
Questions often present realistic clinical scenarios involving investigational new drug applications or institutional review boards. A US candidate might instinctively look for FDA Form 1572, financial disclosure 21 CFR 54, or HIPAA authorizations. Unless explicitly noted, the examination reference framework is rooted in ICH GCP terminology (e.g., "Investigator Agreement", "Ethics Committee Approval", "Subject Confidentiality Protections").
Trap 4: The "Overreaching CRA" Fallacy
In practice, experienced CRAs often develop close working relationships with site coordinators and may be tempted to "fix" errors directly—such as filling in missing CRF fields, making corrections in patient medical charts, or telling an investigator how to treat an adverse event. In the monitoring role, avoid ad hoc performance of site clinical duties, medical decisions or unsupported corrections. Follow documented authority and preserve investigator responsibility. R3 permits sponsor changes to investigator-entered data only when justified, agreed in advance by the investigator and documented; that controlled arrangement does not authorise impersonation or informal edits to meet a deadline. The CRA monitors, verifies, and reports; the Principal Investigator retains total clinical and site authority.
Trap 5: The "Passive Observer" Fallacy
Conversely, some candidates assume that because the CRA is an external monitor, they should take no action when discovering severe non-compliance. In situations where human subject safety is compromised (such as an unapproved protocol amendment altering drug dosing or an unreported life-threatening SAE), the monitor must not merely leave an action item for the next routine visit. The monitor must immediately alert the Principal Investigator and escalate the issue to the sponsor's medical monitor or project manager.
The Clinical Research Associate Role & Exam Preparation Framework
Note
The primary role of the Clinical Research Associate (CRA), as codified in the relevant GCP provisions of ICH E6 Good Clinical Practice, is to serve as the sponsor's designated representative responsible for monitoring the progress of a clinical trial. The CRA acts as the vital bridge between the clinical trial sponsor and the investigative site, ensuring subject protection and scientific veracity.
Clinical trials are highly complex, multi-site human endeavors fraught with logistical, clinical, and ethical risks. While the trial sponsor designs the protocol, provides investigational products, and submits clinical study reports to regulatory authorities, the sponsor relies on the Clinical Research Associate (CRA) —traditionally termed the study monitor—to verify that trial execution at the investigative site mirrors the study protocol and adheres to all applicable standards.
The monitor is neither an administrative clerk nor a medical auditor; the monitor is the proactive guardian of human subject safety, regulatory compliance, and scientific validity in the field.
Official sources
Checked October 18, 2026: ACRP CCRA programme , ACRP Initial Certification Handbook, June 2026 , ACRP CCRA Exam Content Outline .